Tamsulosin Hydrochloride Capsule
Product Images NDC 63187-371

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 63187-371). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over time following single-dose administration of 0.4 mg capsules under fasted and fed conditions. The x-axis represents time in hours up to 36 hours, and the y-axis shows plasma concentration in ng/mL up to 25. Two lines compare fasted (dashed) and fed (solid) states for eight subjects.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' illustrating mean symptom score changes over treatment duration in weeks. It compares three treatment groups: 0.8 mg, 0.4 mg doses of the drug, and placebo, each represented by different markers. Mean change decreases over time, with 0.8 mg showing the greatest reduction, followed by 0.4 mg and placebo.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line chart titled "Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2" showing mean change over duration of treatment in weeks. It compares three groups: 0.8 mg treatment (circles), 0.4 mg treatment (triangles), and placebo (squares). The x-axis represents duration of treatment from 0 to 13 weeks, and the y-axis shows mean change in symptom score from 0 to -11. Both 0.8 mg and 0.4 mg groups show a greater decrease in symptom score over time compared to placebo.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in urine flow rate over a 13-week treatment period plus a last observation carried forward (LOCF) point. The x-axis represents treatment duration in weeks, and the y-axis represents mean change in mL/sec. Three treatments are compared: 0.8 mg dose (circle line), 0.4 mg dose (triangle line), and placebo (square line). The 0.8 mg and 0.4 mg doses show higher mean increases compared to placebo throughout the study.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line chart titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in urine flow rate over 13 weeks of treatment. The x-axis represents duration of treatment in weeks with sample sizes listed below each time point. The y-axis measures mean change in mL/sec. Four lines compare treatments: 0.8 mg dose, 0.4 mg dose, and placebo, showing different trends in peak urine flow rate increase over time.*

FDA Label Image

63187-371-07 (Tamsulosin Fig6)

Tamsulosin HCl 0.4 mg capsules bottle label by Proficient Rx LP. The label states a package size of 90 capsules containing 0.4 mg Tamsulosin hydrochloride USP each. Capsules are described as olive green and orange hard gelatin, printed with 'D' on cap and '53' on body, containing black edible ink and white to off-white beadlets. Manufactured by Aurobindo Pharma Limited, India. Contains QR codes, lot, expiration placeholders, and handling warnings.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing the molecular arrangement including aromatic rings, functional groups, and the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.